Category: Allergan Inc.
A False Claims Act lawsuit unsealed this week accuses aesthetics devices maker Allergan of handing out kickbacks to get doctors to prescribe the company's eye drugs.
MASSDEVICE ON CALL — A pair of Philadelphia ophthalmologists accused medtech company Allergan (NYSE:AGN) of offering doctors illegal kickbacks in exchange for prescriptions of the Allergan's eye drugs.
Celebrity medical advice, like the recent backlash against Allergan's Botox cosmetic injections, can have major repercussions for patients and for the healthcare industry, even when the advice is bad.
MASSDEVICE ON CALL — A pair of reports this week examined the repercussions of celebrity medical advice, from the recent backlash against Botox aesthetic facial injections to actress Jennie McCarthy's avid repudiation of vaccines.
Apollo Endosurgery closes the books on its acquisition of Allergan's obesity intervention business, including the Lap-Band and Orbera technologies, in a deal worth up to $110 million.
Medtech company Allergan (NYSE:AGN) officially dumped its obesity interventions business, consummating with Apollo Endosurgery a deal worth up to $110 million.
Apollo Endosurgery inks a deal with Allergan to acquire its obesity intervention business for up to $110 million.
Almost exactly 1 year after saying it would seek a buyer for its Lap-Band obesity device, Allergan (NYSE:AGN) said today that Apollo Endosurgery agreed to spend up to $110 million on Allergan's obesity intervention business, which includes the Orbera intra-gastric balloon.
FDA regulators grant premarket approval to Allergan's Juvederm Voluma XC injectable gel for aesthetic volume restoration in the face.
Aesthetics company Allergan (NYSE:AGN) notched a U.S. market 1st with FDA approval for its Juvederm Voluma XC facial filler, the only filler indicated for age-related volume restoration in the cheeks.
Allergan board chairman and CEO David Pyott on the "tide" of illegally imported drugs and medical devices.
By David Pyott
The tide of counterfeit and illegally imported drugs and medical devices continues to be strong, as difficult economic times drives demand for seemingly cheaper alternatives. The sophistication of the counterfeiters and illegal importers makes this an increasingly difficult battle to wage, but the threat these illegally imported drugs pose to consumers is real, making it essential that government agencies, with support from industry, continue efforts to help battle this issue.
Allergan beats Wall Street's forecast for its 2nd-quarter results, with a 7.4% increase for its medical device segment.
Allergan (NYSE:AGN) shares ticked up today on strong 2nd-quarter sales and earnings numbers, including a 7.4% top-line gain for its medical device segment.
Irvine, Calif.-based Allergan reported profits of $359.9 million, or $1.17 per share, on sales of $1.60 billion for the 3 months ended June 30, for bottom-line growth of 21.8% on sales growth of 10.2%.